+1 (+3.54%)
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Charming Medical Limited reported its unaudited interim condensed consolidated financial statements for the period ending September 30, 2025. The company experienced a significant decline in revenues totaling 2,159,935 compared to 2,958,508 in the same period last year. A notable net loss of 72,978 was reported, in stark contrast to the net income of 468,817 in the previous year. Additionally, current liabilities have increased, indicating potential financial challenges for the company as it continues operations.
Read more →Charming Medical Limited announced the full exercise of its representative's over-allotment option, resulting in an additional purchase of 240,000 Class A ordinary shares, boosting total gross proceeds from its initial public offering to approximately US$7.36 million. The Class A shares, priced at $4.00 each, commenced trading on the Nasdaq on October 21, 2025. The company plans to utilize the proceeds for business expansion, strategic investments, research and development, and general working capital. The offering was conducted under a firm commitment basis by Cathay Securities, Inc.
Read more →Charming Medical Limited announced the pricing of its initial public offering, offering 1,600,000 Class A ordinary shares at $4.00 each. The company expects to raise about $6.4 million from the IPO, which is set to close on October 22, 2025, contingent upon customary closing conditions. The proceeds will be allocated toward business expansion, strategic investments, research and development, and working capital. The company also has an over-allotment option that could raise total proceeds to approximately $7.36 million.
Read more →